000 | 01020 a2200265 4500 | ||
---|---|---|---|
005 | 20250518075438.0 | ||
264 | 0 | _c20200826 | |
008 | 202008s 0 0 eng d | ||
022 | _a1437-4331 | ||
024 | 7 |
_a10.1515/cclm-2019-0973 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aFerraro, Simona | |
245 | 0 | 0 |
_aMore robust analytical evidence should support the selection of human chorionic gonadotropin assays for oncology application. _h[electronic resource] |
260 |
_bClinical chemistry and laboratory medicine _c02 2020 |
||
300 |
_ae61-e63 p. _bdigital |
||
500 | _aPublication Type: Letter; Comment | ||
650 | 0 | 4 | _aBiological Assay |
650 | 0 | 4 | _aBiomarkers, Tumor |
650 | 0 | 4 | _aChorionic Gonadotropin |
650 | 0 | 4 | _aChorionic Gonadotropin, beta Subunit, Human |
650 | 0 | 4 | _aHumans |
700 | 1 | _aPanteghini, Mauro | |
773 | 0 |
_tClinical chemistry and laboratory medicine _gvol. 58 _gno. 3 _gp. e61-e63 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1515/cclm-2019-0973 _zAvailable from publisher's website |
999 |
_c30463422 _d30463422 |